A SBIR-involved awardee in the firm's ealy years, Evolutionary Genomics (OTC:FNAMO) has not been program active in several years since goig public in 2012. The company is now structured around changing how relevant gene/target discovery and validation is performed during the post-genomics era. The firm has developed a unique, cost-effective technology to identify commercially valuable gene targets by taking advantage of work already done by nature. The Company has a fully operational, patented, gene discovery technology platform, the Adapted Traits Platform, and has already been successfully identifying genes for three years. EGâs Adapted Traits Platform screens for gene patterns indicative of adaptation to a strong selection pressure as a powerful data filter to find key genes. EGâs business model is to capitalize on our unique platform by identifying/validating target genes and working with pharmaceutical and agricultural company partners to commercialize these ge
